Biogen Statistics

Total Valuation

Biogen has a market cap or net worth of EUR 15.31 billion. The enterprise value is 19.13 billion.

Market Cap	15.31B
Enterprise Value	19.13B

Important Dates

The next estimated earnings date is Thursday, May 1, 2025.

Earnings Date	May 1, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+0.21%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	146.00M

Valuation Ratios

The trailing PE ratio is 9.71.

PE Ratio	9.71
Forward PE	n/a
PS Ratio	1.64
PB Ratio	0.95
P/TBV Ratio	29.03
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 6.96, with an EV/FCF ratio of 7.28.

EV / Earnings	12.13
EV / Sales	2.25
EV / EBITDA	6.96
EV / EBIT	9.36
EV / FCF	7.28

Financial Position

The company has a current ratio of 1.35, with a Debt / Equity ratio of 0.40.

Current Ratio	1.35
Quick Ratio	0.77
Debt / Equity	0.40
Debt / EBITDA	2.15
Debt / FCF	2.47
Interest Coverage	9.28

Financial Efficiency

Return on equity (ROE) is 10.36% and return on invested capital (ROIC) is 6.36%.

Return on Equity (ROE)	10.36%
Return on Assets (ROA)	5.29%
Return on Invested Capital (ROIC)	6.36%
Return on Capital Employed (ROCE)	10.31%
Revenue Per Employee	1.23M
Profits Per Employee	207,303
Employee Count	7,605
Asset Turnover	0.35
Inventory Turnover	0.93

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -45.20% in the last 52 weeks. The beta is 0.06, so Biogen's price volatility has been lower than the market average.

Beta (5Y)	0.06
52-Week Price Change	-45.20%
50-Day Moving Average	123.94
200-Day Moving Average	155.90
Relative Strength Index (RSI)	30.40
Average Volume (20 Days)	350

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	1.99

Income Statement

In the last 12 months, Biogen had revenue of EUR 9.35 billion and earned 1.58 billion in profits. Earnings per share was 10.80.

Revenue	9.35B
Gross Profit	7.11B
Operating Income	2.24B
Pretax Income	1.84B
Net Income	1.58B
EBITDA	2.89B
EBIT	2.24B
Earnings Per Share (EPS)	10.80

Full Income Statement

Balance Sheet

The company has 2.29 billion in cash and 6.49 billion in debt, giving a net cash position of -4.19 billion.

Cash & Cash Equivalents	2.29B
Total Debt	6.49B
Net Cash	-4.19B
Net Cash Per Share	n/a
Equity (Book Value)	16.15B
Book Value Per Share	110.74
Working Capital	1.86B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 2.78 billion and capital expenditures -148.46 million, giving a free cash flow of 2.63 billion.

Operating Cash Flow	2.78B
Capital Expenditures	-148.46M
Free Cash Flow	2.63B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 76.12%, with operating and profit margins of 24.00% and 16.87%.

Gross Margin	76.12%
Operating Margin	24.00%
Pretax Margin	19.70%
Profit Margin	16.87%
EBITDA Margin	30.96%
EBIT Margin	24.00%
FCF Margin	28.13%

Dividends & Yields

Biogen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.21%
Shareholder Yield	-0.21%
Earnings Yield	10.30%
FCF Yield	17.17%

Stock Splits

The last stock split was on January 18, 2001. It was a forward split with a ratio of 3.

Last Split Date	Jan 18, 2001
Split Type	Forward
Split Ratio	3

Scores

Biogen has an Altman Z-Score of 3.26.

Altman Z-Score	3.26
Piotroski F-Score	n/a